Outcomes in patients (n (%)) with no or small hypoattenuation v large hypoattenuation on initial CT
| Outcome event | Time (days) | CT findings within 6 h of stroke | ||||||
|---|---|---|---|---|---|---|---|---|
| Hypoattenuation ⩽33% MCA territory | Hypoattenuation >33% MCA territory | |||||||
| Placebo | rt-PA | OR (95) CI) | Placebo | rt-PA | OR (95) CI) | |||
| PH | 1 | 14/278 (5)2-150 | 47/269 (17)2-150 | 3.99 (2.14–7.44) | 0/21 (0)2-150 | 9/31 (29)2-150 | — | |
| Mortality | 7 | 20/279 (7) | 25/272 (9) | 1.31 (0.71–2.42) | 6/21 (29) | 9/31 (29) | 1.02 (0.30–3.48) | |
| Mortality | 90 | 41/279 (15) | 51/272 (19) | 1.34 (0.85–1.34) | 6/21 (29) | 15/31 (48) | 2.34 (0.72–7.63) | |
| Rankin = 0+1 | 90 | 81/277 (29)2-150 | 108/265 (41)2-150 | 1.66 (1.17–2.38) | 3/21 (14) | 2/31 (6) | 0.41 (0.06–2.72) | |
↵2-150 2p<0.01, Fisher’s exact test between pairs within same hypoattenuation class.
PH=parenchymal haematoma. These data from the ECASS show for patients with an ischaemic oedema >33% of the MCA territory (as detected as hypoattenuation on the initial CT scan) an increase in PH, a significantly higher early and late mortality, and a significantly smaller proportion of patients with beneficial outcome in the rt-PA group. The 52 patients with large ischaemic lesions were identified by an independent CT scan evaluation. Small differences in the incidence of outcome events are due to missing values. — = Not calcuable.